Analyst Research

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: Pechala's Reports
$15.00
Provider: Reuters Investment Profile
$20.00
Provider: Thomson Reuters Stock Report
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Mallinckrodt Plc Announces New Drug Application Accepted For Review By FDA


Thursday, 22 Aug 2013 07:00am EDT 

Mallinckrodt Plc announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the New Drug Application (NDA) for MNK-395. MNK-395 is referred to in the application as PENNSAID (diclofenac sodium topical solution) 2% w/w, studied in the treatment of the pain of osteoarthritis of the knee. 

Related Company News

Company Quote

114.2
1.02 +0.90%
1 May 2015